Immunome, Inc.
US ˙ NasdaqCM ˙ US45257U1088

SecurityIMNM / Immunome, Inc.
InstitutionVanguard Group Inc
Latest Disclosed Ownership0 shares
Ownership 0.00%
Vanguard Group Inc ownership in IMNM / Immunome, Inc.

2026-03-26 - Vanguard Group Inc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 0 shares of Immunome, Inc. (US:IMNM). This represents 0.0 percent ownership of the company. In their previous filing dated 2025-07-29 , Vanguard Group Inc had reported owning 4,524,952 shares, indicating a decrease of -100.00 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2026-03-26 2026-03-26 13G/A 4,524,952 0 -100.00 0.00 -100.00
2025-07-29 2025-07-29 13G 3,003,438 4,524,952 50.66 5.20 8.11
2025-01-30 2025-01-30 13G/A 3,131,568 3,003,438 -4.09 4.81 -7.68
2024-11-12 2024-11-12 13G/A 3,131,568 3,131,568 0.00 5.21 0.00
2024-11-04 2024-11-04 13G/A 3,131,568 5.21

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-01-29 2025-12-31 13F IMMUNOME COM 45257U108 6,038,414 1,144,788 23.39 129,705 126.35 0.0019
2025-11-07 2025-09-30 13F IMMUNOME COM 45257U108 4,893,626 368,674 8.15 57,304 36.17 0.0009
2025-08-11 2025-06-30 13F IMMUNOME COM 45257U108 4,524,952 217,761 5.06 42,082 45.18 0.0007
2025-05-09 2025-03-31 13F IMMUNOME COM 45257U108 4,307,191 1,303,753 43.41 28,987 -9.12 0.0005
2025-02-11 2024-12-31 13F IMMUNOME COM 45257U108 3,003,438 -128,130 -4.09 31,897 -30.33 0.0006
2024-11-13 2024-09-30 13F IMMUNOME COM 45257U108 3,131,568 210,356 7.20 45,784 29.53 0.0008
2024-08-13 2024-06-30 13F IMMUNOME COM 45257U108 2,921,212 901,474 44.63 35,347 -29.09 0.0007
2024-05-10 2024-03-31 13F IMMUNOME COM 45257U108 2,019,738 279,712 16.08 49,847 167.74 0.0010
2024-03-11 2023-12-31 13F/A-1 IMMUNOME COM 45257U108 1,740,026 1,343,697 339.04 18,618 462.65 0.0004
2024-02-14 2023-12-31 13F IMMUNOME COM 45257U108 1,740,026 1,343,697 18,618 0.0004
2023-12-18 2023-09-30 13F/A-1 IMMUNOME COM 45257U108 396,329 22,451 6.00 3,309 11.90 0.0001
2023-11-14 2023-09-30 13F IMMUNOME COM 45257U108 396,329 22,451 3,309 0.0000
2023-08-14 2023-06-30 13F IMMUNOME COM 45257U108 373,878 0 0.00 2,957 58.55 0.0001
2023-07-14 2023-03-31 13F/A-1 IMMUNOME COM 45257U108 373,878 0 0.00 1,866 125.79 0.0000
2023-05-15 2023-03-31 13F IMMUNOME COM 45257U108 373,878 0 1,866 0.0000
2023-02-10 2022-12-31 13F IMMUNOME COM 45257U108 373,878 193 0.05 826 -50.21 0.0000
2022-11-14 2022-09-30 13F IMMUNOME COM 45257U108 373,685 3,149 0.85 1,659 39.53 0.0000
2022-08-12 2022-06-30 13F IMMUNOME COM 45257U108 370,536 0 0.00 1,189 -43.52 0.0000
2022-05-13 2022-03-31 13F IMMUNOME COM 45257U108 370,536 -5,822 -1.55 2,105 -56.85 0.0000
2022-02-14 2021-12-31 13F IMMUNOME COM 45257U108 376,358 3,878 1.04 4,878 -46.22 0.0001
2021-11-12 2021-09-30 13F IMMUNOME COM 45257U108 372,480 70,388 23.30 9,070 73.56 0.0002
2021-08-13 2021-06-30 13F IMMUNOME COM 45257U108 302,092 147,863 95.87 5,226 0.02 0.0001
2021-05-14 2021-03-31 13F IMMUNOME COM 45257U108 154,229 154,229 5,225 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.